ActivePhase 2Phase 3ACTRN12611000350921

The effects of memantine versus placebo on visual functions of patient with optic neuritis

In patients with optic neuritis, is Memantine as good as or better than placebo for improving visual functions?

Sponsor

Tehran University of Medical sciences

Enrollment

60 participants

Start Date

Apr 1, 2010

Study Type

Interventional

Conditions

isolated optic neuritis

Summary

Evaluation of the neuroprotective effect of Memantine in visual function of patients with optic neuritis. Our hypothesis was that Memantine helps for better improvement of visual function in acute optic neuritis.

Eligibility

Sex: Both males and femalesMin Age: 10 YearssMax Age: 50 Yearss

Plain Language Summary

Simplified for easier understanding

This trial tests whether memantine, a medication typically used for Alzheimer's disease, can protect and restore vision in people experiencing acute optic neuritis (sudden inflammation of the optic nerve). Patients aged 10-50 with optic neuritis that started within the past 8 days are eligible to participate.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Memantine tablets for treatment group for 3 weeks orally(5mg/day for the first week and 10 mg/ day for the next two weeks)

Locations(1)

Iran, Islamic Republic Of

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12611000350921